Effectiveness of a standard secondary coronary prevention program: not obligate.
作者信息
Onat Altan
机构信息
Department of Cardiology, Cerrahpaşa Faculty of Medicine, İstanbul University; İstanbul-Turkey.
出版信息
Anatol J Cardiol. 2016 Feb;16(2):92-3. doi: 10.14744/AnatolJCardiol.2015.15958.
Abstract
摘要
相似文献
1
Effectiveness of a standard secondary coronary prevention program: not obligate.
Anatol J Cardiol. 2016 Feb;16(2):92-3. doi: 10.14744/AnatolJCardiol.2015.15958.
2
3
Effectiveness of nonpharmacological secondary prevention of coronary heart disease.
Eur J Cardiovasc Prev Rehabil. 2010 Dec;17(6):688-700. doi: 10.1097/HJR.0b013e32833a1c95.
4
Effectiveness of nurse-led patient-centered care behavioral risk modification on secondary prevention of coronary heart disease: A systematic review.
Int J Nurs Stud. 2018 Aug;84:28-39. doi: 10.1016/j.ijnurstu.2018.04.012. Epub 2018 Apr 22.
5
The distinct role of secondary prevention in patients with prior coronary interventions.
EuroIntervention. 2009 May;5 Suppl D:D131-8.
6
7
Administration and effects of secondary prevention measures in coronary heart disease patients from Serbia according to gender and cardiometabolic risk.
Acta Cardiol. 2010 Aug;65(4):407-14. doi: 10.2143/AC.65.4.2053899.
8
Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association.
Circulation. 2015 Mar 10;131(10):927-64. doi: 10.1161/CIR.0000000000000182. Epub 2015 Feb 9.
9
Role of depression in secondary prevention of Chinese coronary heart disease patients receiving percutaneous coronary intervention.
PLoS One. 2017 Dec 21;12(12):e0187016. doi: 10.1371/journal.pone.0187016. eCollection 2017.
10
A comparison of secondary prevention practice in poststroke and coronary heart disease patients.
Public Health. 2016 Aug;137:64-72. doi: 10.1016/j.puhe.2016.02.003. Epub 2016 Mar 17.
本文引用的文献
1
Using a standardized follow-up program to improve coronary heart disease secondary prevention.
Anatol J Cardiol. 2016 Feb;16(2):84-91. doi: 10.5152/akd.2015.5571. Epub 2015 Apr 24.
2
Prediction by Low Plasma HbA1c of Mortality, Cardiac and Noncardiac Disease Risk: Modulation by Diabetic Status and Sex.
J Investig Med. 2015 Aug;63(6):821-7. doi: 10.1097/JIM.0000000000000216.
3
Low "quotient" Lp(a) concentration mediates autoimmune activation and independently predicts cardiometabolic risk.
Exp Clin Endocrinol Diabetes. 2015 Jan;123(1):11-8. doi: 10.1055/s-0034-1385922. Epub 2014 Oct 14.
4
Renal "hyperfiltrators" are at elevated risk of death and chronic diseases.
BMC Nephrol. 2014 Oct 2;15:160. doi: 10.1186/1471-2369-15-160.
5
Paradoxical association of lipoprotein measures with incident atrial fibrillation.
Circ Arrhythm Electrophysiol. 2014 Aug;7(4):612-9. doi: 10.1161/CIRCEP.113.001378. Epub 2014 May 25.
6
Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity.
Expert Rev Cardiovasc Ther. 2014 Jun;12(6):667-79. doi: 10.1586/14779072.2014.910114.
7
Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk.
Endocrine. 2015 Feb;48(1):218-26. doi: 10.1007/s12020-014-0269-z. Epub 2014 May 3.
8
Apparently "low" serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes.
Anadolu Kardiyol Derg. 2014 Feb;14(1):26-33. doi: 10.5152/akd.2013.5009. Epub 2013 Dec 9.
9
The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?
Diabetes. 2014 Jan;63(1):332-342. doi: 10.2337/db13-1144. Epub 2013 Oct 2.
10
Increased apolipoprotein A-I levels mediate the development of prehypertension among Turks.
Anadolu Kardiyol Derg. 2013 Jun;13(4):306-14. doi: 10.5152/akd.2013.106. Epub 2013 Apr 11.
Zotero 插件